These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 33031827)

  • 21. Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression.
    Nian F; Zhu J; Chang H
    Biochem Biophys Res Commun; 2019 Jul; 514(4):1140-1146. PubMed ID: 31103265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
    Jia C; Kong D; Guo Y; Li L; Quan L
    Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
    Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
    Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.
    Fu Y; Liu X; Zhang F; Jiang S; Liu J; Luo Y
    Cell Death Dis; 2019 Apr; 10(4):319. PubMed ID: 30967527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
    Tang JX; Chen Q; Li Q; He YH; Xiao D
    Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
    Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
    J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenomics and chemical library screens reveal a novel SCF
    Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
    Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
    Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxic Bone Marrow Stromal Cells Secrete miR-140-5p and miR-28-3p That Target SPRED1 to Confer Drug Resistance in Multiple Myeloma.
    Zhang H; Du Z; Tu C; Zhou X; Menu E; Wang J
    Cancer Res; 2024 Jan; 84(1):39-55. PubMed ID: 37756570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression.
    Yang C; Yuan W; Yang X; Li P; Wang J; Han J; Tao J; Li P; Yang H; Lv Q; Zhang W
    Mol Cancer; 2018 Jan; 17(1):19. PubMed ID: 29386015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-218 contributes to drug resistance in multiple myeloma via targeting LRRC28.
    Chen H; Cao W; Chen J; Liu D; Zhou L; Du F; Zhu F
    J Cell Biochem; 2021 Apr; 122(3-4):305-314. PubMed ID: 33417267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling.
    Wang L; Cao J; Tao J; Liang Y
    Expert Opin Drug Saf; 2024 Mar; 23(3):277-286. PubMed ID: 37642368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
    Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
    Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
    Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
    J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
    Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
    Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circular RNA ITCH suppressed prostate cancer progression by increasing HOXB13 expression via spongy miR-17-5p.
    Wang X; Wang R; Wu Z; Bai P
    Cancer Cell Int; 2019; 19():328. PubMed ID: 31827402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circlular RNA BARD1 (Hsa_circ_0001098) overexpression in breast cancer cells with TCDD treatment could promote cell apoptosis via miR-3942/BARD1 axis.
    Zhao J; Zou H; Han C; Ma J; Zhao J; Tang J
    Cell Cycle; 2018; 17(24):2731-2744. PubMed ID: 30521417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long Noncoding RNA H19 Promotes Tumorigenesis of Multiple Myeloma by Activating BRD4 Signaling by Targeting MicroRNA 152-3p.
    Zheng JF; Guo NH; Zi FM; Cheng J
    Mol Cell Biol; 2020 Jan; 40(3):. PubMed ID: 31712391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.